Suppr超能文献

骨巨细胞瘤病灶内广泛刮除、烧灼及聚甲基丙烯酸甲酯骨水泥填充治疗的中期结果:一项回顾性病例系列研究。

Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series.

机构信息

Department of Orthopaedic Surgery and Traumatology, Marmara University, School of Medicine, İstanbul, Turkey.

出版信息

Acta Orthop Traumatol Turc. 2020 Sep;54(5):524-529. doi: 10.5152/j.aott.2020.19082.

Abstract

OBJECTIVE

The aim of this study was to present the mid-term functional outcomes and recurrence rate in patients with giant cell tumor of bone (GCTB) treated by intralesional extended curettage, electrocauterization, and polymethylmethacrylate (PMMA) cementation.

METHODS

In this retrospective observational study, 79 consecutive patients (41 females, 38 males; mean age=39 years; age range=19-62 years) who were diagnosed and treated for GCTB between 2005 and 2017 were identified from hospital medical records. All patients were treated by intralesional extended curettage using high-speed burr, electrocauterization of the cavity, and filling the defect with PMMA. No additional local adjuvants were used. The mean follow-up period was 47 months (range=24-96). The tumors were graded according to the radiological classification system described by Campanacci. Functional outcomes were evaluated using the Musculoskeletal Tumor Society Score (MSTS) preoperatively, one year postoperatively, and at the final follow-up. Postoperative complications and recurrence rates were recorded.

RESULTS

Twenty-nine tumors were located in the distal femur, 23 in the proximal tibia, nine in the distal radius, five in the proximal humerus, five in the pelvis, three in the proximal fibula, two in the distal ulna, two in the distal tibia, and one in the second metatarsal. According to Campanacci classification, 37 tumors were grade III, 32 grade II, and 10 grade I. The mean MSTS score was 46.1% (range 40.2 to 71.4%) preoperatively, 91.7% (range 73.3% to 100%) one year postoperatively, and 86.3 % (range 66.2% to 96,1%) at the final follow-up. The overall complication rate was 7.6%; which included local tumor recurrence in four patients, superficial wound infection in one, and deep wound infection in another. The recurrence rate was 5.1% (4 patients). Recurrent tumors were located at the distal femur in three patients and proximal tibia in one.

CONCLUSION

With satisfactory functional results and low recurrence rates at the mid-term follow-up, GCTB can be treated effectively with intralesional extended curettage, electrocauterization, and PMMA cementation.

LEVEL OF EVIDENCE

Level IV, Therapeutic study.

摘要

目的

本研究旨在介绍采用病灶内广泛切除、电灼和聚甲基丙烯酸甲酯(PMMA)骨水泥填充治疗骨巨细胞瘤(GCTB)患者的中期功能结果和复发率。

方法

在这项回顾性观察研究中,从医院病历中确定了 79 名连续患者(41 名女性,38 名男性;平均年龄 39 岁;年龄范围 19-62 岁),这些患者在 2005 年至 2017 年间被诊断为 GCTB 并接受治疗。所有患者均采用高速磨头进行病灶内广泛切除、电灼、PMMA 填充骨腔。未使用其他局部辅助剂。平均随访时间为 47 个月(范围 24-96)。肿瘤根据 Campanacci 放射学分类系统分级。术前、术后 1 年和最终随访时使用肌肉骨骼肿瘤学会评分(MSTS)评估功能结果。记录术后并发症和复发率。

结果

29 个肿瘤位于股骨远端,23 个位于胫骨近端,9 个位于桡骨远端,5 个位于肱骨近端,5 个位于骨盆,3 个位于腓骨近端,2 个位于尺骨远端,2 个位于胫骨远端,1 个位于第二跖骨。根据 Campanacci 分级,37 个肿瘤为 III 级,32 个为 II 级,10 个为 I 级。术前平均 MSTS 评分为 46.1%(范围 40.2-71.4%),术后 1 年为 91.7%(范围 73.3%-100%),最终随访时为 86.3%(范围 66.2%-96.1%)。总体并发症发生率为 7.6%;包括 4 例局部肿瘤复发,1 例浅表伤口感染,1 例深部伤口感染。复发率为 5.1%(4 例)。复发性肿瘤位于 3 例患者的股骨远端和 1 例患者的胫骨近端。

结论

在中期随访时,具有令人满意的功能结果和较低的复发率,骨巨细胞瘤可以通过病灶内广泛切除、电灼和 PMMA 骨水泥填充进行有效治疗。

证据水平

IV 级,治疗研究。

相似文献

2
Long bones giant cells tumors: treatment by curretage and cavity filling cementation.
Orthop Traumatol Surg Res. 2009 Oct;95(6):402-6. doi: 10.1016/j.otsr.2009.07.004. Epub 2009 Sep 19.
4
Treatment options for recurrent giant cell tumors of bone.
J Cancer Res Clin Oncol. 2009 Jan;135(1):149-58. doi: 10.1007/s00432-008-0427-x. Epub 2008 Jun 3.
5
6
Extended intralesional curettage preferred over resection-arthrodesis for giant cell tumour of the distal radius.
Eur J Orthop Surg Traumatol. 2020 Jan;30(1):11-17. doi: 10.1007/s00590-019-02496-2. Epub 2019 Jul 11.
7
Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications.
Clin Orthop Relat Res. 2017 Mar;475(3):776-783. doi: 10.1007/s11999-016-4755-x.

引用本文的文献

4
Exploring versatile applications of a vacuum-assisted bone harvester in orthopedic surgery.
BMC Musculoskelet Disord. 2024 Aug 31;25(1):688. doi: 10.1186/s12891-024-07786-3.
7
9
Management of the Cavity After Removal of Giant Cell Tumor of the Bone.
Front Surg. 2021 Jul 29;8:626272. doi: 10.3389/fsurg.2021.626272. eCollection 2021.

本文引用的文献

2
Treatment and recurrence of giant cell tumors of bone - A retrospective cohort from a developing country.
Ann Med Surg (Lond). 2019 Oct 15;48:29-34. doi: 10.1016/j.amsu.2019.10.010. eCollection 2019 Dec.
4
A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities.
Acta Orthop Traumatol Turc. 2019 Sep;53(5):376-380. doi: 10.1016/j.aott.2019.05.005. Epub 2019 Jun 26.
6
Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Clin Orthop Relat Res. 2018 Sep;476(9):1773-1782. doi: 10.1007/s11999.0000000000000243.
7
Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Acta Orthop Traumatol Turc. 2017 Jan;51(1):1-6. doi: 10.1016/j.aott.2016.03.004. Epub 2016 Oct 24.
8
Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Eur J Cancer. 2016 May;59:1-12. doi: 10.1016/j.ejca.2016.01.006. Epub 2016 Mar 15.
9
Giant Cell Tumor of Bone - An Overview.
Arch Bone Jt Surg. 2016 Jan;4(1):2-9.
10
Joint preserved reconstruction after curettage in giant cell tumor of bone arising in the distal radius: Case report.
Int J Surg Case Rep. 2015;16:181-3. doi: 10.1016/j.ijscr.2015.10.007. Epub 2015 Oct 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验